The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Allogene Therapeutics Inc (NASDAQ: ALLO) was $2.76 for the day, down -2.82% from the previous closing price of $2.84. In other words, the price has decreased by -$2.82 from its previous closing price. On the day, 2.15 million shares were traded. ALLO stock price reached its highest trading level at $2.91 during the session, while it also had its lowest trading level at $2.705.
Ratios:
Our analysis of ALLO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.58 and its Current Ratio is at 12.58. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
On December 08, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $7.Citigroup initiated its Buy rating on December 08, 2023, with a $7 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 30 ’24 when Parker Geoffrey M. bought 190 shares for $3.60 per share. The transaction valued at 683 led to the insider holds 819,590 shares of the business.
MESSEMER DEBORAH M. sold 18,640 shares of ALLO for $50,317 on Dec 18 ’23. The Director now owns 62,456 shares after completing the transaction at $2.70 per share. On Aug 07 ’23, another insider, Mayo Stephen, who serves as the Director of the company, sold 10,000 shares for $4.29 each. As a result, the insider received 42,855 and left with 25,328 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 471195488 and an Enterprise Value of 113117896. For the stock, the TTM Price-to-Sale (P/S) ratio is 2944.92 while its Price-to-Book (P/B) ratio in mrq is 0.80. Its current Enterprise Value per Revenue stands at 1190.715 whereas that against EBITDA is -0.377.
Stock Price History:
The Beta on a monthly basis for ALLO is 0.87, which has changed by -0.5174825 over the last 52 weeks, in comparison to a change of 0.23099434 over the same period for the S&P500. Over the past 52 weeks, ALLO has reached a high of $6.89, while it has fallen to a 52-week low of $2.23. The 50-Day Moving Average of the stock is -35.61%, while the 200-Day Moving Average is calculated to be -25.66%.
Shares Statistics:
ALLO traded an average of 2.33M shares per day over the past three months and 2170650 shares per day over the past ten days. A total of 170.72M shares are outstanding, with a floating share count of 105.75M. Insiders hold about 38.06% of the company’s shares, while institutions hold 60.14% stake in the company. Shares short for ALLO as of 1713139200 were 31360608 with a Short Ratio of 13.49, compared to 1710460800 on 27749018. Therefore, it implies a Short% of Shares Outstanding of 31360608 and a Short% of Float of 28.54.
Earnings Estimates
Allogene Therapeutics Inc (ALLO) is currently under the scrutiny of 15.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$0.41 for the current quarter, with a high estimate of -$0.22 and a low estimate of -$0.64, while EPS last year was -$0.68. The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.23 and low estimates of -$0.54.
Analysts are recommending an EPS of between -$0.91 and -$2.1 for the fiscal current year, implying an average EPS of -$1.68. EPS for the following year is -$1.6, with 15.0 analysts recommending between -$0.24 and -$2.2.
